MedTech AI Inc.

MedTech AI Inc. (“MedTech” or the “Company”) is a Canadian, private funding and strategic partner which has entered into an agreement with Oxford Immune Algorithmics (“OIA”), a UK-based medical technology to acquire 38% of OIA.

Under the terms of the agreement, at such time as OIA becomes listed for trading on a recognized stock exchange (anticipated to occur by Q3 2022), MedTech shareholders will exchange their MedTech shares for pro-rata shares of OIA, the publicly listed company.